Hosted on MSN19h
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Whole genome sequencing poised to transform newborn screening programmes
Newborn screening is transforming, as advances in genomic sequencing pave the way for earlier, more accurate diagnoses of ...
BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Zacks.com on MSN6h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
Nanoparticles deliver microRNAs to muscle stem cells for potential muscular dystrophy treatment
In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...